SUPERNUS PHARMACEUTICALS, INC. Annual Operating Income (Loss) in USD from 2010 to 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Supernus Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2010 to 2024.
  • Supernus Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was $21.4M.
  • Supernus Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was $81.7M.
  • Supernus Pharmaceuticals, Inc. annual Operating Income (Loss) for 2024 was $81.7M.
  • Supernus Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$5.27M, a 111% decline from 2022.
  • Supernus Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was $46.1M, a 46.4% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.